Navigation Links
USDA Agrees to Grant Conditional License to Bioniche for its E. coli O157:H7 Cattle Vaccine
Date:2/5/2008

BELLEVILLE, ON, Feb. 5 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today received notice from the United States Department of Agriculture (USDA) that the latest data for its E. coli O157:H7 cattle vaccine "meets the 'expectation of efficacy' standard" and is eligible for a conditional license, providing that the Company develops a plan "that would collect sufficient data to move the product to full licensure". The conditional license, when granted, will provide the Company full access to the U.S. market with two restrictions: At least one step in the manufacturing process must be performed in the United States and Bioniche will not be permitted to use a trademark name for the vaccine.

The Bioniche vaccine is the world's first vaccine that may be used as an on-farm intervention to reduce the amount of E. coli O157:H7 shed by cattle. Bioniche and its collaborators have been moving the vaccine towards commercial availability for eight years and it has been extensively tested at the University Nebraska-Lincoln, with efficacy results now being published in peer-reviewed scientific journals, most recently, the Journal of Food Protection, in November, 2007. The E. coli O157:H7 cattle vaccine will be manufactured in the Bioniche production facility in Belleville, Ontario, Canada where a two-year, $25 million expansion is taking place. Vaccine supply will be limited during this manufacturing expansion period.

"This is a large step forward for the E. coli O157:H7 vaccine," said Graeme McRae, President & CEO of Bioniche Life Sciences Inc. "The granting of a U.S. conditional license will permit U.S. beef and dairy producers access to a scientifically-validated means to reduce the risk of E. coli O157:H7 contamination."

Rick Culbert, President of Bioniche Food Safety, added, "There are an estimated 97 million cattle in the United States, many of which carry an
'/>"/>

SOURCE Bioniche Life Sciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Boston Scientific Agrees To Sell Fluid Management and Venous Access Businesses to Avista Capital Partners for $425 Million
2. eResearchTechnology (eRT) Agrees to Acquire the Centralized ECG Business of Covance
3. Covance Agrees to Enter Strategic Relationship with eResearchTechnology to Offer its Clients eRTs Centralized Cardiac Safety Services
4. CSC Agrees to Acquire First Consulting Group
5. Medical Services International Agrees to Retail the VScan Hepatitis B&C Test Kits in SE Asia
6. Wild American Shrimp Board Agrees To Implement New Self-Funding Measures
7. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
8. Ludwig Institute for Cancer Research receives NHMRCs largest 2009 grant
9. Neighborhood ethnic density associated with risk of psychosis among immigrants in the Netherlands
10. Simons Foundation grant boosts brain tumor research
11. Verathon Inc., maker of GlideScope(R) Video Laryngoscopes, Introduces Free Grant Writing Kit for EMS Professionals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2008)...eClaim Revenue Gateway Alleviates Insurance Claim ...roviders , , ATLANTA, Dec. 2 /PRNewswire-Fi...day announced a new healthcare receivables solutio...s well as hospitals. SunTrust eClaim Revenue Gatew...issions as well as payment collection and processi...
(Date:12/2/2008)...o., Dec. 2 MicroPhage, Inc., htt... M. Taussig, MD has joined,the company,s Board of...onal,Jewish Medical and Research Center in Denver...espiratory diseases, from 1993 to 2006. His medic...I have followed MicroPhage extensively and am impr...
(Date:12/2/2008)...s Missing Opportunities to Connect - , , - ...escription Drug Abuse Dangers - , , NEW YOR...Partnership for a Drug-Free America and MetLife Fo...ail or text messaging to communicate with their t...nect with their kids about drug and alcohol use. T...
(Date:12/2/2008)...OCKVILLE, Md., Dec. 2 F...iods and increased supervision of work hour limits...nment, according to a new Institute of Medicine re... and Quality. , , The report is the result...ewed the relationship between residents, work sche...
Breaking Medicine News(10 mins):Health News:Healthcare Providers Now Able to Perform Real-Time Patient Eligibility Verification 2Health News:Healthcare Providers Now Able to Perform Real-Time Patient Eligibility Verification 3Health News:Healthcare Providers Now Able to Perform Real-Time Patient Eligibility Verification 4Health News:MicroPhage Selects Lynn Taussig, MD for Board of Directors 2Health News:Bridging the Technology Gap: Study Confirms Teens Open to Discussing Drugs and Alcohol With Parents By Email, Cell Phones 2Health News:Bridging the Technology Gap: Study Confirms Teens Open to Discussing Drugs and Alcohol With Parents By Email, Cell Phones 3Health News:New Report Recommends Strategies to Reduce Medical Resident Fatigue-Related Errors and Improve Training 2Health News:New Report Recommends Strategies to Reduce Medical Resident Fatigue-Related Errors and Improve Training 3Health News:New Report Recommends Strategies to Reduce Medical Resident Fatigue-Related Errors and Improve Training 4
...isphosphonates are at an increased risk of jaw or ...nates are used to treat cancer-related bone lesio...duced bone density. Several recent studies have f...of intravenous bisphosphonates and osteonecrosis o...
...ople have been bitten and injured by a jackal in B...abies vaccines in the government hospitals to trea... has attacked and injured villagers - including wo...villages under the Manjhagarh block of the distric...
...al progress in curbing the spread of polio with ju...r compared to 676 last year, says WHO. Of the 8...m Uttar Pradesh and 17 from Bihar, it says. 'The...polio in 2007 is 213 compared with 585 for the sam...
...n Pakistan, evoking mixed reactions. <brThei...omething extraordinary. Then the Lahore High Cour...omes as a pleasant surprise is the decision of the... Court to release them on bail and hear their app...
Other Medicine News:Health News:Bisphosphonate Increases the Risk of Jaw Bone Deterioration 2Health News:India Records Substantial Decline in Polio Cases 2Health News:Same Sex Pair Get Relief in Pakistan 2
(Date:12/1/2008)...e study shows the Prox1 gene is a two-way switch t...ells to be reprogrammed so that they lose their id...s , , MEMPHIS, Tenn., Dec. 1 /PRNewswire-US...search Hospital have discovered that a certain dif...entity that it requires the constant expression of...
(Date:12/1/2008)...STGARD, Denmark, December 1 /PRNewswire-FirstCall/...07 with the intent to procure an MVA-based,third...ernment Services,Canada, on behalf of the Canadia...ontract to Bavarian Nordic for the delivery of IMV... to use IMVAMUNE(R) as part of the,country,s bio-...
(Date:12/1/2008)...GO, Dec. 1 Vical Incorpo...t of a $1.0 million milestone payment from Merck &... of a Phase I clinical trial of an investigational...vaccine is based on Vical,s DNA gene delivery tech...riptase (hTERT). hTERT is the subject of separate ...
(Date:11/28/2008)...RLITZ, Germany, November 28 German...eadership in specialized HIV monitoring and,AIDS ...merging countries. In,the year 2008, 2.5 million ...le, robust and highly affordable "CyFlow" system, ...ing with HIV/AIDS. Due to introduction of the,Par...
Breaking Medicine Technology:Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 2Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 3The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 2The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 3Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial 2German Innovation for HIV/AIDS Diagnostics has Been Used 2.5 Million Times in 2008 2Fantastic photographs of fluorescent fish 4890 1Old and new therapies combine to tackle atherosclerosis 7697 1Old and new therapies combine to tackle atherosclerosis 7697 2Old and new therapies combine to tackle atherosclerosis 7697 3Water purification down the nanotubes 7695 1Water purification down the nanotubes 7695 2Cadence Pharmaceuticals Updates Omigard 28TM 29 Clinical Timeline 3058 1Cadence Pharmaceuticals Updates Omigard 28TM 29 Clinical Timeline 3058 2Cadence Pharmaceuticals Updates Omigard 28TM 29 Clinical Timeline 3058 3Cadence Pharmaceuticals Updates Omigard 28TM 29 Clinical Timeline 3058 4
...o Company Oncology Programs to be Presented, SOUTH...-FirstCall/ -- Cytokinetics, Incorporated announce...data will be,presented at the 2007 Annual Meeting ...ACR) to be held from April 14- 18, 2007 in,Los Ang...cology,programs at Cytokinetics and will present d...
...--(BUSINESS WIRE)--Apr 9, 2007 -,GlaxoSmithKline (...DLR) today announced data from Study 767905/014 an...rogram for,alvimopan (Entereg/Entrareg(R))., Study...(12,month) study, was designed to evaluate the lon... twice daily in patients taking,opioids for chroni...
Other Medicine Technology:Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 2Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 3Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 4Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 5Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 6Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 7GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 2GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 3GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 4GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 5GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 6GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 7
Wilbrandt-binkhorst irrigating cannula.
Binkhorst, length 18 mm.
Wilbrandt-Binkhorst Cannula have a smooth blunt tip end opening.
Army navy retractor set.
Medicine Products: